What is ASCQR?

The Ambulatory Surgery Center Quality Reporting program is a complex program with multiple reporting requirements and deadlines. ASCQR is designed to promote higher quality, more efficient health care for Medicare beneficiaries through measurement. Under ASCQR, quality data reporting requirements for care rendered in an ASC setting were implemented starting with claims submitted for services beginning October 1, 2012.

ASCQR is required. Will you go it alone or get experienced help?

If you do not participate or fail to meet the ASCQR requirements, your center may see a 2% reduction to your CMS payment.

Helping ASCs with Quality Reporting

Miraca ASC Consulting Services help your center make sense of the requirements and deadlines throughout the year.

  • Our team of expert consultants work with you to ensure the ASC has an active Security Administrator for the QualityNet Secure Portal and is properly registered with the CDC to report ASC 8
  • We guide you through the registration process which can take up to 4 weeks to complete
  • Miraca’s staff consultants work with your billing team, security administrator and physicians to help you confirm that you’re meeting all program requirements
    • For your Billing Team
      We provide workflow support and guidance to your billing personnel to report ASC measures 1–5.
    • For your Security Administrator
      ASC 6, 7, 9, & 10 through Quality Net. ASC 8 must be reported through the CDC website. Miraca will also work with the Security Administrator to submit ASC-6 (Safe Surgery Checklist Use) and ASC-7 (ASC Facility Volume Data on Selected ASC Surgical Procedures).
    • For your Physicians
      ASC-9 (Endoscopy/Polyp Surveillance: Appropriate Follow-Up Interval for Normal Colonoscopy in Average Risk Patients), and ASC-10 (Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use).

ASCQR MEASURES

  • Measures 1–5 are claims-based—Miraca helps you ensure that G codes are included for revenue optimization
  • Measures 6, 7, 8 are web-based—we help you maximize your participation
  • Measures 9 and 10 are specific to pathology—we help you address workflow and pathology input

QUALITY MEASURES

GIQuIC is a GI-specific registry that captures the quality measures from the surgery center. It’s a qualified clinical data registry (QCDR) and is CMS-approved for reporting PQRS quality measures.

As a fee-based service, Miraca has enhanced interfaces with both ProVation MD and gMed to auto-populate the entry of pathology data in GIQuIC.

TECHNOLOGY OPTIMIZATION

  • Benefit from Miraca’s bi-directional ERW interfaces for submitting requisitions and receiving reports
  • Make the most of your technology through Miraca training on your interfaces and your practice workflow

HIPAA TRAINING

  • Get compliance training for your existing staff and new hires

SECURITY RISK ASSESSMENT

  • Understand where and how to improve your security
  • Stay compliant with security requirements

ACS/HOSPITAL COMPARE REVIEW

  • Understand the steps you can take to boost your CMS public ratings
  • See how the CMS website compares the ASCs in your market
  • Collect patient surveys—in 2018, at least 300 patient surgery surveys must be collected
    • Utilize our unique ERW interfaces to send procedure notes and images

ASCQR Web-Based Measures

Data collected January 1–December 31, 2015, should be submitted January 1–August 15, 2016, to determine the 2017 payment rate.

  • ASC-6: Safe Surgery Checklist Use
  • ASC-7: ASC Facility Volume Data on Selected ASC Surgical Procedures
  • ASC-8: Influenza Vaccination Coverage among Healthcare Personnel (data collection period: Oct. 1, 2015–March 31, 2016; submission period: Oct. 1, 2015–May 15, 2016)
  • ASC-9: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients
  • ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use
  • ASC-11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NOTE: Data Submission Voluntary)

Collect data in January 1–December 31, 2016, to be submitted January 1–August 15, 2017, to determine the 2018 payment rate:

  • ASC-6: Safe Surgery Checklist Use
  • ASC-7: ASC Facility Volume Data on Selected ASC Surgical Procedures
  • ASC-8: Influenza Vaccination Coverage among Healthcare Personnel (data collection period: Oct. 1, 2015-March 31, 2016; submission period: Oct. 1, 2015-May 15, 2016)
  • ASC-9: Endoscopy/Polyp Surveillance: Appropriate Follow-up Interval for Normal Colonoscopy in Average Risk Patients
  • ASC-10: Endoscopy/Polyp Surveillance: Colonoscopy Interval for Patients with a History of Adenomatous Polyps – Avoidance of Inappropriate Use
  • ASC-11: Cataracts: Improvement in Patient’s Visual Function within 90 Days Following Cataract Surgery (NOTE: Data Submission Voluntary)

*National Healthcare Safety Network

Contact Miraca to learn how we can assist your practice.
Email HealthITConsulting@MiracaLS.com or call 866.588.3280.

Miraca has been extremely helpful to our office with Meaningful Use. It is such a complex task to undertake, and having knowledgeable people from Miraca to assist with each stage, work flow, and administration is invaluable. You guys have saved us countless hours. Everyone we’ve encountered from Miraca from the beginning like yourself [Rick Ludwico], and now with Joy [Rios], and Amy [Schmid] have been terrific. We count on you guys, and you have guided us throughout the whole process, making it so much easier than it would be otherwise!.
— Pam Kefer, Office Manager
Wallach Derma Center, Danville, Calif.


READ MORE
Learn about Miraca's unmatched quality. We provide our clients with access to the highest quality AP services.

Recent News


April 18, 2017

Miraca Research News: Philips receives FDA clearance to market Philips IntelliSite Pathology Solution for primary diagnostic use in the US

Pathologists at Miraca Life Sciences contributed significantly in the development of a new product from Philips, the IntelliSite Pathology Solution. As one of four clinical study sites, Miraca Life Sciences participated in “one of the largest studies ever conducted to directly compare the use of digital pathology to optical microscopes.” At Miraca, participation in the Philips study was a project of Miraca […]

Continue reading


April 11, 2017

Ten Research Projects from Miraca Life Sciences Accepted for DDW Conference

IRVING, Texas, April 12, 2017 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Digestive Disease Week® conference (DDW), which will be held May 6–9 in Chicago. DDW is the world’s largest gathering of physicians, researchers and industry in the fields of gastroenterology, […]

Continue reading


March 27, 2017

Simponi® is Sixth Drug in InformTx™ Therapeutic Drug Monitoring Service from Miraca Life Sciences

IRVING, Texas, March 28, 2017 — Miraca Life Sciences, the largest U.S. independent anatomic pathology laboratory, continues to expand its InformTx™ therapeutic drug monitoring (TDM) capabilities, now testing for Simponi (golimumab) as well as patient-developed antibodies to Simponi. This is the first TDM assay available in the United States for Simponi. With this addition, Miraca Life Sciences now performs TDM […]

Continue reading


November 30, 2016

Stelara® Now Available for Therapeutic Drug Monitoring from Miraca Life Sciences

IRVING, Texas, December 1, 2016 — Miraca Life Sciences, the largest U.S. independent anatomic pathology lab, has expanded its InformTx™ therapeutic drug monitoring service for drugs that treat inflammatory bowel disease (IBD) with the addition of Stelara (ustekinumab).

Miraca Life Sciences continues to perform therapeutic drug monitoring (TDM) for Remicade® (infliximab), Humira® (adalimumab), Cimzia® (Certolizumab pegol) and Entyvio® (vedolizumab). Since […]

Continue reading


August 10, 2016

Ten Research Projects from Miraca Life Sciences Accepted for ACG Conference

IRVING, Texas, August 10, 2016 — Ten research projects from the GI pathologists at Miraca Life Sciences, the nation’s largest independent anatomic pathology lab, have been accepted for presentation at the Annual Meeting of the American College of Gastroenterology (ACG), which will be held October 14–19 in Las Vegas.

Authors from Miraca Life Sciences are linked below to their profile […]

Continue reading